Surging Global Medical Cannabis Market Fueled by Growing Awareness and Legalization Trends, Forecast to 2030
The global medical cannabis market has witnessed remarkable growth, with its valuation reaching USD $9,882.21 million in 2022, and is anticipated to soar to USD $53,886.43 million by 2030, registering a CAGR of 23.61%. Cannabis, a chemical plant rich in medicinal properties, is utilized as a raw material by various pharmaceutical firms for producing drugs targeting diverse therapeutic applications. The extract from cannabis is employed to treat numerous conditions, including Alzheimer’s disease, migraines, arthritis, chronic pain, and more.
Market growth is primarily driven by the rising awareness of various medical applications, such as appetite enhancement, pain management, and reduced eye pressure. Moreover, the growing number of countries legalizing medical cannabis usage worldwide is expected to positively impact market growth. Additionally, the surge in mergers and acquisitions within the medical cannabis sector will further propel the market.
However, the global medical cannabis market faces a significant restraint, as the US Food and Drug Administration (FDA) has not approved medical cannabis for cancer treatment.
The market is segmented by route of administration, including oral, inhalation, and topical methods, and by application, encompassing Alzheimer’s disease, migraines, arthritis, chronic pain, and others. Geographically, the market spans across North America, Latin America, Europe, Asia Pacific, and the Middle East & Africa.
Key players in the global medical cannabis market include GW Pharmaceuticals PLC, The Peace Naturals Project, Insys Therapeutics Inc., Cannabis Sativa Inc., Green Relief Inc., Medical Marijuana Inc., Aurora Cannabis Inc., Aphria Incorporation, MedReleaf Corporation, and Canopy Growth Corporation.
Market Segments:
- Route of Administration
- Oral
- Inhalation
- Topical
- Application
- Alzheimer’s disease
- Migraine
- Arthritis
- Chronic Pain
- Others
- Region
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East & Africa
Latest News
Reunion Neuroscience to be Acquired by MPM BioImpact in $13.1 Million All-Cash Deal
LOS ANGELES-- Reunion Neuroscience Inc. a clinical-stage biopharmaceutical company specializing in innovative therapies for underserved mental health conditions, has announced a definitive arrangement agreement with MPM BioImpact, a leading biotechnology investment firm. Under the agreement, ...
California’s Regulated Cannabis Market Sees Decline in Sales and Tax Revenue in Q1 2023
LOS ANGELES-- California's hopes of increased consumer participation in the regulated cannabis market did not translate into a boost in licensed retail sales or state tax revenue during the first quarter of 2023. According to ...
C21 Investments Repays $30 Million Debt to CEO Sonny Newman
LOS ANGELES-- C21 Investments Inc., a vertically integrated cannabis company, announced today the successful completion of the full repayment of its $30 million senior secured note owed to Sonny Newman, the Company's President and Chief ...